| Date Filed | Type | Description |
| 07/07/2015 |
SC 13G/A
| PERKINS CAPITAL MANAGEMENT INC reports a 0% stake in Uroplasty, Inc. |
| 07/07/2015 |
SC 13G/A
| PERKINS CAPITAL MANAGEMENT INC reports a 0% stake in Uroplasty, Inc. |
| 05/13/2015 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities [Amend] |
| 04/02/2015 |
4
| WEHRWEIN SVEN (Director) has filed a Form 4 on UROPLASTY INC|
Txns:
| Disposed/sold 43,625 shares
@ $0
Disposed/sold 6,175 options to buy
@ $4.16, valued at
$25.7k
Disposed/sold 5,475 options to buy
@ $4.83, valued at
$26.4k
Disposed/sold 7,025 options to buy
@ $3.76, valued at
$26.4k
Disposed/sold 8,625 options to buy
@ $3.46, valued at
$29.8k
|
|
| 04/02/2015 |
4
| Stauner James P (Director) has filed a Form 4 on UROPLASTY INC |
| 04/02/2015 |
4
| Hammers Darin (Sr VP Global Sales & Marketing) has filed a Form 4 on UROPLASTY INC|
Txns:
| Disposed/sold 131,800 shares
@ $0
Disposed/sold 100,000 options to buy
@ $2.69, valued at
$269k
|
|
| 04/02/2015 |
4
| Kill Robert (President and CEO) has filed a Form 4 on UROPLASTY INC |
| 04/02/2015 |
4
| ROCHE KEVIN H (Director) has filed a Form 4 on UROPLASTY INC|
Txns:
| Disposed/sold 25,000 shares
@ $0
Disposed/sold 57,125 shares
@ $0 |
|
| 04/02/2015 |
4
| Paulus Kenneth H (Director) has filed a Form 4 on UROPLASTY INC|
Txns:
| Disposed/sold 14,475 shares
@ $0 |
|
| 04/02/2015 |
4
| Reynolds Brett (Sr. Vice President and CFO) has filed a Form 4 on UROPLASTY INC |
| 04/01/2015 |
SC 13D/A
| UROPLASTY INC reports a 0% stake in Cogentix Medical, Inc. |
| 03/31/2015 |
8-K
| Form 8-K - Current report |
| 03/10/2015 |
8-K
| Investor presentation |
| 03/10/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 03/10/2015 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/03/2015 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"MINNEAPOLIS, March 3, 2015 -- Uroplasty, Inc. , a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, will host a meeting for shareholders and analysts on Thursday, March 12, 2015, beginning at 3:00 pm Central Time, at Uroplasty’s corporate headquarters in Minnetonka, Minnesota. Rob Kill, President and Chief Executive Officer, will host the meeting, which will feature a discussion of the proposed merger between Uroplasty and Vision-Sciences and a presentation by Dr. Roland Ugarte, who will discuss the roles that Urgent PC and EndoSheath have in today’s urology practices. Dr. Ugarte is a Senior Partner of Urology Associates, a Minneapolis-based group of 15 urologic surgeons providing comprehensive care to over 75,000 ..." |
|
| 03/03/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 02/23/2015 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 02/17/2015 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 6.2% stake in Uroplasty, Inc. |
| 02/13/2015 |
SC 13G/A
| Visium Asset Management, LP reports a 0% stake in Uroplasty, Inc. |
| 02/10/2015 |
SC 13G/A
| MASSACHUSETTS FINANCIAL SERVICES CO reports a 0% stake in Uroplasty, Inc. |
| 02/10/2015 |
SC 13G/A
| MASSACHUSETTS FINANCIAL SERVICES CO reports a 10.1% stake in Uroplasty, Inc. |
| 02/06/2015 |
10-Q
| Quarterly Report for the period ended December 31, 2014 |
| 02/04/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 01/30/2015 |
4
| ROCHE KEVIN H (Director) has filed a Form 4 on UROPLASTY INC|
Txns:
| Bought 7,100 shares
@ $1.23, valued at
$8.7k
Bought 1,100 shares
@ $1.24, valued at
$1.4k
Bought 16,800 shares
@ $1.25, valued at
$21k
Bought 25,000 shares
@ $1.21, valued at
$30.3k
|
|
| 01/30/2015 |
4
| Reynolds Brett (Senior Vice President and CFO) has filed a Form 4 on UROPLASTY INC |
| 01/29/2015 |
4
| Kill Robert (President and CEO) has filed a Form 4 on UROPLASTY INC |
| 01/28/2015 |
SC 13G/A
| PERKINS CAPITAL MANAGEMENT INC reports a 5.8% stake in Uroplasty, Inc. |
| 01/27/2015 |
8-K
| Other Events |
| 01/27/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 01/26/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 01/23/2015 |
SC 13G
| Amici Capital, LLC reports a 6.8% stake in Uroplasty, Inc. |
| 01/22/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"MINNEAPOLIS, January 22, 2015 -- Uroplasty, Inc. , a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2015 third quarter ended December 31, 2014. Global revenue for the Company’s Urgent ® PC Neuromodulation System grew 14.5% to $4.4 million, a new quarterly revenue record, as compared to $3.9 million in the third quarter of the prior year. Global Macroplastique sales were $2.0 million during the third quarter as compared to $2.3 million in the third quarter of fiscal 2014. Total revenue for the third quarter of fiscal 2015 was $6.7 million, a 4.2% increase from the same quarter in the prior year. The impact of changes in foreign currency exchange rates negatively imp..." |
|
| 01/12/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
|